WO2016079276A1 - Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse - Google Patents

Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse Download PDF

Info

Publication number
WO2016079276A1
WO2016079276A1 PCT/EP2015/077174 EP2015077174W WO2016079276A1 WO 2016079276 A1 WO2016079276 A1 WO 2016079276A1 EP 2015077174 W EP2015077174 W EP 2015077174W WO 2016079276 A1 WO2016079276 A1 WO 2016079276A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
exposed
seq
ccr2
fragment
Prior art date
Application number
PCT/EP2015/077174
Other languages
English (en)
Inventor
Jonathan Zalevsky
Bernard SOUBERBIELLE
Original Assignee
Takeda Gmbh
Millennium Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Millennium Pharmaceuticals Inc. filed Critical Takeda Gmbh
Publication of WO2016079276A1 publication Critical patent/WO2016079276A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

L'invention concerne des combinaisons comprenant des antagonistes anti-GM-CSF et des antagonistes anti-CCR2 pour traiter et prévenir des infections provoquées par des agents induisant une fièvre hémorragique ou pour moduler la réponse cellulaire ou immunitaire d'un individu qui a été exposé, infecté ou susceptible d'être infecté par de tels agents, par exemple, le virus Ebola.
PCT/EP2015/077174 2014-11-21 2015-11-20 Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse WO2016079276A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462083152P 2014-11-21 2014-11-21
US62/083,152 2014-11-21
US201462088221P 2014-12-05 2014-12-05
US62/088,221 2014-12-05

Publications (1)

Publication Number Publication Date
WO2016079276A1 true WO2016079276A1 (fr) 2016-05-26

Family

ID=54695715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/077174 WO2016079276A1 (fr) 2014-11-21 2015-11-20 Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse

Country Status (1)

Country Link
WO (1) WO2016079276A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191291A (zh) * 2016-08-15 2016-12-07 中国人民解放军军事医学科学院微生物流行病研究所 rs1042658在预测新布尼亚病毒引起的发热伴血小板减少综合征死亡风险中的应用
WO2023072916A1 (fr) 2021-10-27 2023-05-04 Granite Bio Ag Anticorps ciblant ccr2

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057226A1 (fr) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Anticorps humanises anti-ccr2 et procedes d'utilisation de ces anticorps
WO2006111353A2 (fr) * 2005-04-18 2006-10-26 Micromet Ag Neutralisants d'anticorps du facteur de stimulation des colonies de granulocytes/macrophages (gm-csf) humain
WO2009038760A2 (fr) * 2007-09-18 2009-03-26 Amgen Inc. Protéines de liaison à un antigène gm-csf humain
WO2010124136A1 (fr) * 2009-04-24 2010-10-28 Delta Vidyo, Inc. Écumoire vidéo efficace
WO2013004806A1 (fr) * 2011-07-06 2013-01-10 Morphosys Ag Associations thérapeutiques d'anticorps anti-cd20 et anti-gm-csf, et leurs utilisations
AU2013201228A1 (en) * 2006-02-08 2013-03-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057226A1 (fr) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Anticorps humanises anti-ccr2 et procedes d'utilisation de ces anticorps
WO2006111353A2 (fr) * 2005-04-18 2006-10-26 Micromet Ag Neutralisants d'anticorps du facteur de stimulation des colonies de granulocytes/macrophages (gm-csf) humain
AU2013201228A1 (en) * 2006-02-08 2013-03-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2009038760A2 (fr) * 2007-09-18 2009-03-26 Amgen Inc. Protéines de liaison à un antigène gm-csf humain
WO2010124136A1 (fr) * 2009-04-24 2010-10-28 Delta Vidyo, Inc. Écumoire vidéo efficace
WO2013004806A1 (fr) * 2011-07-06 2013-01-10 Morphosys Ag Associations thérapeutiques d'anticorps anti-cd20 et anti-gm-csf, et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. SIERRA-FILARDI ET AL: "CCL2 Shapes Macrophage Polarization by GM-CSF and M-CSF: Identification of CCL2/CCR2-Dependent Gene Expression Profile", THE JOURNAL OF IMMUNOLOGY, vol. 192, no. 8, 17 March 2014 (2014-03-17), US, pages 3858 - 3867, XP055242994, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1302821 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191291A (zh) * 2016-08-15 2016-12-07 中国人民解放军军事医学科学院微生物流行病研究所 rs1042658在预测新布尼亚病毒引起的发热伴血小板减少综合征死亡风险中的应用
WO2023072916A1 (fr) 2021-10-27 2023-05-04 Granite Bio Ag Anticorps ciblant ccr2

Similar Documents

Publication Publication Date Title
US11845801B2 (en) IL-15 prodrugs and methods of use thereof
EP3057994B1 (fr) Commutateurs de cellules t à récepteur d'antigène chimère peptidique et leurs utilisations
ES2569217T3 (es) Agente para tratar enfermedades
KR101970025B1 (ko) Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP5661553B2 (ja) 改良された抗体分子を含有する製剤
EP2330193B1 (fr) Molécule d'anticorps améliorée contre le récepteur a il-6
AU2005311101B2 (en) Anti-IL-IRI single domain antibodies and therapeutic uses
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
JP2019514889A (ja) 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
KR20210054528A (ko) Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
TW202039572A (zh) 雙官能抗pd-1/il-7分子
AU2020337999A1 (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment
KR20190002563A (ko) 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법
TW202222823A (zh) 投與治療劑量的雙特異性ｔ細胞接合分子治療癌症之方法
WO2016079276A1 (fr) Utilisation d'un antagoniste anti-gm-csf et d'un antagoniste anti-ccr2 pour traiter une maladie infectieuse
US20220389099A1 (en) Methods for treating leukemia
WO2016081801A1 (fr) Utilisation d'un antagoniste anti-ccr2 dans le traitement d'une maladie infectieuse
TW202021983A (zh) 用於嗜伊紅性氣喘之抗il-33療法
WO2023143535A1 (fr) Anticorps ciblant il-18bp et son utilisation
US20240117030A1 (en) Multispecific antibodies and uses thereof
RU2796586C2 (ru) Антитела к cd6 для лечения тяжелой астмы
WO2016079277A1 (fr) Utilisation d'un antagoniste anti-gm-csf dans le traitement d'une maladie infectieuse
TW202304981A (zh) 抗ｉｌ－２７抗體及其用途
TW202108621A (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途
BR112020017605A2 (pt) Anticorpos anti-trem-1 e usos dos mesmos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15798062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15798062

Country of ref document: EP

Kind code of ref document: A1